圣湘生物：2025年营收16.48亿元，净利润同比降28.10%

Core Viewpoint - Shengxiang Bio announced a revenue target of 1.648 billion yuan for 2025, representing a year-on-year growth of 13.04%, while net profit attributable to shareholders is expected to decline by 28.10% to 198 million yuan [1] Financial Performance - Revenue for 2025 is projected at 1.648 billion yuan, a 13.04% increase year-on-year [1] - Total profit is expected to be 175 million yuan, with net profit attributable to shareholders at 198 million yuan, reflecting a decline of 28.10% [1] - Deducting non-recurring gains, net profit is forecasted at 165 million yuan, down 18.64% year-on-year [1] Strategic Initiatives - The company continues to advance its "integrated diagnosis and treatment" strategy, with R&D investment around 310 million yuan, accounting for nearly 20% of revenue [1] - Multiple innovative products have been launched, and nearly 10 new Class III medical device registrations have been obtained [1] - The company has fully acquired Zhongshan Haiji and holds a controlling stake in Hong'an Jiyuan, deepening its strategic layout [1] - Several affiliated and controlled companies have received relevant accolades, injecting new momentum into development [1]